Replies to post #9464 on Amarin Corp Plc (AMRN)

[Laurent Maldague]

Thanks for the reply. The resolvins research is extremely interesting in itself and bodes well for Amarin. However regarding the Lovaza sNDA, I have no idea how they can suddenly have a label expansion approval this fast and out of the blue. (and specifically, label expansion for what??).

I'm still sticking with the the line "provides for a revised package insert
in response to our letter dated Decem
ber 18, 2012. " Wouldn't this letter say "providing for label expansion bla bla" if the sNDA was for that? To me, revised package insert sounds like something regarding semantics rather than something material.


I'll accept that the possibilities for things to spring into action regarding GSK/AMRN/resolvins as you conjecture are still there, but I don't believe the hard evidence is in yet. I certainly am appreciative of the insights though and sincerely do hope your insights get transferred to the parties mentioned above.